Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. - Wikidata - wikimedia - TriplyDB

Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q33862741

about

HIV infection, aging, and immune function: implications for cancer risk and prevention Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010 Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy.Residual immune dysregulation syndrome in treated HIV infection.Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters.Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis Biomarkers of immune dysfunction in HIV.Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients Association of Toll-like receptor polymorphisms with HIV status in North Americans Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in Zambia Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death Identification of three immunologic correlates for HIV type 1 pathogenesis in youth Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers.Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.Multisite comparison of high-sensitivity multiplex cytokine assays.Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study HIV pathogenesis: the host.HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease.Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction.Associations of Circulating Soluble Tumor Necrosis Factor-α Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug Users with or at High Risk for HIV Infection T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.

P2860

Q27004165-8C73883D-EB89-4717-A454-5B349337DA34 Q27690715-62730642-2CC0-4D9A-A1C2-59F6CAFDE23C Q28088557-C96C5FC6-A21B-4887-8D06-4E251B8AABFE Q28480936-0B4A53E6-3D89-4CE8-A46F-0BCA08CF827D Q31146636-02E3A280-84E0-46E4-93AB-E1DE18344E9F Q31152445-BD0534FF-BA71-410E-AC52-1A4EDB1D3ACF Q33889154-4F3ABDFD-16C7-44BD-8DE1-3F54DAF4DF86 Q33897898-7FFC9906-F970-4F79-84E1-07BBF6C896AB Q34016057-80702DF5-8870-4AA9-A232-DEEFBE6F1D5C Q34020121-8793C534-0060-4152-B1DE-E128D15F7A08 Q34091313-8C1CF6C8-8F52-4F6D-996F-F6E3A9C6AE3A Q34202331-C5584B0B-1A36-49C8-8839-C77F30386DFF Q34229695-C0ECC082-6E79-47DA-B806-C131D81ED686 Q34315572-48A456DA-2870-4F98-8323-4AF815EDD65B Q34387349-2AB938E4-F1DA-4879-9255-A78370EEF2DF Q34494208-B70B9D3E-2E3F-4B63-9802-910A26302105 Q34505245-982F628E-A90F-4A90-ABB2-306603E2DAFC Q34546742-7593EBBC-2C04-49F4-9BF3-BEAD7904A722 Q34627162-F5BE878F-4D15-432D-B71C-07D1C55109B3 Q34634839-7B25F107-7427-452A-A877-D749EDEE1A2B Q34642208-FDF0D1D7-08A0-4C3D-A197-7FE4CA2C6B5F Q34796153-EE4CB03B-B386-421A-8294-7FF2CD59F620 Q34812071-6581F3E1-FE21-4308-97A9-FC8811AB31A3 Q34980769-39BA27AE-25ED-42E3-AD81-8A8B1CE90DC1 Q34988273-0AF901A0-2801-4B85-95EE-DAC1648FEBF2 Q35003524-BA4652BE-19D2-4F2E-8DC8-94B88A00069A Q35006056-0F1C9CBC-84DE-4140-9BE9-B955BC543325 Q35023537-693DD529-FCD9-4CB0-9256-B5790ABDDC03 Q35078598-818F96EB-CE52-4B88-B129-BB34C42D36E7 Q35102167-5E360406-BAB8-4AE7-9BA2-04F247183A35 Q35138815-B16CD867-F01B-4250-AAB5-22B102E4EC9D Q35655728-FE965CD9-7E86-4B79-AA25-993A10B52DD7 Q35873402-68FA855E-909F-4E0C-872C-2EB95CE76E8F Q36068935-7E26B3B6-02DA-424F-8014-4B36ADD2FF1F Q36186538-EED4C340-DB88-4FF5-AE46-415C68C0CB26 Q36279270-18ADD898-B9D7-4561-8B1C-9B5D58B7C9F5 Q36291721-0E2AD25D-497F-40F3-B4E5-FA8924DE20F8 Q36330047-7F15AEEE-6162-42BD-B9EB-11F7C03D0FE9 Q36359499-88E96EC7-E16E-431E-901E-C8FF47D76587 Q36377944-326C9460-B34B-4DC9-ADE3-59D079192C4D

P2860

Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q33862741

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pretreatment levels of soluble ...... active antiretroviral therapy.

@ast

Pretreatment levels of soluble ...... active antiretroviral therapy.

@en

type

label

Pretreatment levels of soluble ...... active antiretroviral therapy.

@ast

Pretreatment levels of soluble ...... active antiretroviral therapy.

@en

prefLabel

Pretreatment levels of soluble ...... active antiretroviral therapy.

@ast

Pretreatment levels of soluble ...... active antiretroviral therapy.

@en

P1433

Q33862741-50AC8FA5-2A6E-4288-B2CD-DDC500DCC72D

P1476

Q33862741-D04A3362-7823-4E14-9032-CFF4DA33E60F

P2093

Q33862741-00627D8D-0F01-4F31-BF44-652AB3EB7981

Q33862741-01BBD603-6E06-4F5B-BE5E-76D6018184B2

Q33862741-0CDD8CEE-D2B6-4709-80D2-7D192D7E3565

Q33862741-198F4E18-525D-4D73-A158-49B4E864054D

Q33862741-24DECA17-1C6A-417B-9E3B-095001804885

Q33862741-99817CA8-40CA-4F71-A6BA-EA62B997E79E

Q33862741-C30B7964-4759-405C-B793-7275E88E8363

P2860

Q33862741-00718CC5-0070-4E77-887A-400C291ED9AB

Q33862741-015BBEBA-717F-4283-9523-E7D57C91C496

Q33862741-017C78ED-ED94-4E6B-83FB-DEA52BCBFF56

Q33862741-02602762-AA38-40EF-BBB3-879E92599767

Q33862741-053FD892-AE62-44B4-AB64-CCAD2E52366A

Q33862741-08D14A44-BCFF-474D-95CE-0F1C027DF518

Q33862741-0EE90720-9C7B-431C-AFD8-87CF16193BE5

Q33862741-160CB038-0106-4674-95FF-583CCF055293

Q33862741-18A96836-9BBF-48B7-8541-DFC6BFED560A

Q33862741-2159A577-AE72-45A8-B74C-AD5EE3887BCF

P304

Q33862741-094E84E3-A949-45B7-B3A2-B170C51CF991

P31

Q33862741-C625BD14-60F8-4395-9F29-1DEFADD9FFB8

P356

Q33862741-9659C789-9368-4F95-8AE3-89D02C2986F4

P407

Q33862741-9E01B109-AF2E-47AE-915F-80D10ED13B42

P433

Q33862741-8A25662A-4D70-4008-9E9C-C8337905293C

P478

Q33862741-A660A918-397B-49F1-832B-ACAD95C1852C

P50

Q33862741-5C88B586-5335-439B-92E6-CCC61614A792

Q33862741-BBBE0AA9-7E1B-47E5-A00D-D03C8E7AD553

P577

Q33862741-34E8B579-4E21-4008-8165-6E4A7E3D22D5

P5875

Q33862741-0AB4B4A1-B063-4C8A-9C43-4C6DF9C02A20

P698

Q33862741-D076F127-C888-4F29-8593-37E94EF97B47

P921

Q33862741-16876fcf-986a-45c6-b131-df0992b66e02

Q33862741-369AE127-5628-4FDE-BAD8-86960D83799A

P932

Q33862741-E8B18D69-7ACA-4E35-B501-079FDB663A04

P356

P1433

The Journal of Infectious Diseases

P1476

Pretreatment levels of soluble ...... active antiretroviral therapy.

@en

P2093

Alan Landay

http://www.w3.org/2001/XMLSchema#string

Gregory K Robbins

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Rajesh T Gandhi

http://www.w3.org/2001/XMLSchema#string

Rhoderick N Machekano

http://www.w3.org/2001/XMLSchema#string

Richard B Pollard

http://www.w3.org/2001/XMLSchema#string

Robert C Kalayjian

http://www.w3.org/2001/XMLSchema#string

P2860

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

Immune activation and inflammation in HIV-1 infection: causes and consequences

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

P304

1796-1805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/652750

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

Benigno Rodriguez

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44577360

http://www.w3.org/2001/XMLSchema#string

P698

20446847

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2873127

http://www.w3.org/2001/XMLSchema#string